ArticleFrontiers in immunology2024
Single-cell RNA sequencing highlights the influence of innate and adaptive immune response mechanisms in psoriatic arthritis.
Article in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Genetic Evidence Linking Immune Cell Subsets to Psoriatic Arthritis Susceptibility: A Mendelian Randomization Study.Psoriasis (Auckland, N.Z.) · 2026Article
- Beyond cytokine blockade: could CAR-Tregs open a new era of tissue-targeted immune tolerance in psoriatic arthritis?Frontiers in immunology · 2026Article
- Systemic Psoriasis: From Molecular Mechanisms to Global Management Strategies.Clinical reviews in allergy & immunology · 2025Review
- Single-cell sequencing reveals cellular heterogeneity and molecular mechanisms in tendon and enthesis injury repair.Frontiers in physiology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Psoriatic arthritis (PsA) is a chronic immune-mediated inflammatory disease displaying heterogeneous symptoms. However, the association between the clinical heterogeneity of PsA and disease immunopathogenesis remains poorly understood complicating diagnostic precision. A knowledge gap remains on whether it is possible to distinguish the clinical PsA phenotypes on the immune cellular level. The primary aim of the study was to explore the differences in gene expression profiles comparing PsA patients without cutaneous psoriasis (PsA-only) and PsA patients with cutaneous psoriasis (PsA/PsC). The secondary aim was to describe the transcriptional patterns in PsA patients compared with healthy controls. Methods: The study applied single-cell RNA sequencing (scRNAseq) using the BD Rhapsody™ Single-Cell Analysis System to evaluate peripheral blood mononuclear cells (PBMCs) from 70 PsA patients and 10 healthy controls. Differential expression (DE) analysis and gene set enrichment analysis (GSEA) were applied to evaluate differentially expressed genes (DEGs) and enriched signaling pathways, respectively. Results: The DE analysis and GSEA comparing PsA-only and PsA/PsC patients with healthy controls, respectively, revealed divergent results involving both innate and adaptive immune mechanisms, which might be associated with differences in the clinical phenotype. No DEGs were discovered in the direct comparison of PsA-only and PsA/PsC patients. Discussion: The single-cell transcriptome profiling provided insight into the heterogeneity of PsA patients as the discovered DEGs and the GSEA did demonstrate differences in signaling associated with inflammation comparing PsA patients with and without cutaneous psoriasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.